CymaBay Therapeutics Inc. (CBAY) financial statements (2020 and earlier)

Company profile

Business Address 7575 GATEWAY BOULEVARD
NEWARK, CA 94560
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1911799717423531
Cash and cash equivalents2549231081224
Short-term investments16613074934237
Other undisclosed cash, cash equivalents, and short-term investments(0)0(0)(3)00 
Receivables  5 000
Prepaid expense1311120
Other current assets 000 00
Other undisclosed current assets11(0)0(0)(0)(0)0
Total current assets:20318210419433732
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment2300000
Other noncurrent assets0211000
Total noncurrent assets:3511000
TOTAL ASSETS:20618710419433733
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7675473
Accounts payable3211121
Accrued liabilities3465332
Employee-related liabilities2    21
Interest and dividends payable  0000 
Debt0 33110
Restructuring reserve3     
Other undisclosed current liabilities79611126
Total current liabilities:18141696209
Noncurrent Liabilities
Long-term debt and lease obligation2 36934
Long-term debt, excluding current maturities  36934
Operating lease, liability2
Liabilities, other than long-term debt 2 0000
Deferred rent credit 2
Other liabilities   0000
Total noncurrent liabilities:2236934
Total liabilities:19161915152414
Stockholders' equity
Stockholders' equity attributable to parent, including:186170854281419
Common stock0000000
Additional paid in capital812694536427424395367
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)(0)0
Accumulated deficit(626)(523)(451)(423)(396)(381)(349)
Warrants and rights outstanding     146
Other undisclosed stockholders' equity attributable to parent     (14)(6)
Total stockholders' equity:186170854281419
TOTAL LIABILITIES AND EQUITY:20618710419433733

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:  10    
Operating expenses(108)(73)(31)(26)(26)(24)(9)
Operating loss:(108)(73)(21)(26)(26)(24)(9)
Nonoperating income (expense)5(0)(5)011(7)0
Investment income, nonoperating5410000
Other nonoperating income (expense) (3)(6)011(7)0
Interest and debt expense (0)(1)(1)(1)(1)(1)
Loss before gain (loss) on sale of properties:(103)(73)(28)(27)(16)(32)(10)
Other undisclosed net income 0     
Net loss attributable to parent:(103)(73)(28)(27)(16)(32)(10)
Preferred stock dividends and other adjustments      305
Other undisclosed net loss available to common stockholders, basic      (51)
Net income (loss) available to common stockholders, basic:(103)(73)(28)(27)(16)(32)244
Dilutive securities, effect on basic earnings per share (0)  (0) (254)
Net loss available to common stockholders, diluted:(103)(73)(28)(27)(16)(32)(10)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(103)(73)(28)(27)(16)(32)(10)
Other comprehensive income (loss)0(0)(0)0(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(103)(73)(28)(27)(16)(32)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: